心臓POC検査市場：製品タイプ、バイオマーカータイプ、エンドユーザー別-2025-2030年の世界予測

心臓POC検査市場は、2023年に83億1,000万米ドルと評価され、2024年には93億8,000万米ドルに達すると予測され、CAGR 13.14％で成長し、2030年には197億4,000万米ドルに達すると予測されています。

心臓POC検査（POCT）とは、心臓発作や心不全などの心疾患を迅速に特定することを目的とし、患者の診療現場またはその近くで実施される医療診断検査を指します。心臓POCTの必要性は、依然として世界の死亡原因の上位を占める心血管系疾患の迅速な診断と治療が急務であることに起因します。心臓POCTの主な用途には、救急部、集中治療室、その他迅速な結果が患者の転帰を大幅に改善する重要な場面が含まれます。最終用途は病院、診療所、外来診療、在宅医療にまで及び、ヘルスケア提供における多用途性と重要性を反映しています。

市場の観点からは、心血管疾患の有病率の増加と小型化バイオセンサーなどの技術の進歩が、心臓POCTの成長を促進しています。特に遠隔地や資源が限られた環境での迅速検査に対する需要の高まりが、その重要性をさらに高めています。しかし、高度なPOCTデバイスの高コスト、規制上のハードル、検査室での検査と比較した精度のばらつきといった課題が、市場の成長を阻害する可能性があります。重要な機会は、費用対効果の高いソリューションと精度の向上によるアクセスの拡大にあり、潜在的にはAIと機械学習を統合して予測分析を改善することにあります。

このような課題にもかかわらず、心臓POCT市場は、特に1検体から包括的なパネル検査を提供できる多項目POCT機器の開発において、大きなイノベーションの機会を提供しています。技術開発者とヘルスケアプロバイダーとの共同開発を促進することで、より使いやすく効率的な検査を生み出すことができます。企業は、ヘルスケアインフラが限られているが心疾患の有病率が高い地域に焦点を当て、アンメットニーズを満たすオーダーメイドのソリューションを開発することで利益を得ることができます。

まとめると、心臓POCT市場はコストや規制の問題などの制約に直面する一方で、技術的な改善やアプリケーションの拡大に取り組むことで、絶好の機会を提供しています。戦略的な技術革新と連携努力により、これらの機会を活用し、市場の持続的成長と患者ケアの向上を促進することができます。

市場力学：急速に進化する心臓POC検査市場の主要市場インサイトを公開

心臓POC検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心血管障害の人口増加
  • POC検査イントロダクション対する政府の好意的な取り組み
  • 世界各国のヘルスケア支出の改善
• 市場抑制要因
  • 心臓POC検査に使用される材料やコンポーネントのコスト変動
• 市場機会
  • 心臓POC検査の改善と継続的進歩
  • 検査能力を向上させるための新しいバイオマーカー開発の進展
• 市場の課題
  • 心臓POC検査における運用と技術の複雑さ

ポーターのファイブフォース：心臓POC検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：心臓POC検査市場における外部からの影響の把握

外部マクロ環境要因は、心臓POC検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析心臓POC検査市場における競合情勢の把握

心臓POC検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス心臓POC検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、心臓POC検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨心臓POC検査市場における成功への道筋を描く

心臓POC検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口における心血管疾患の発生率の増加
    • POC検査イントロダクション向けた政府の好意的な取り組み
    • 世界中の経済におけるヘルスケア費支出の改善
  • 抑制要因
    • 心臓POC検査に使用される材料と部品のコストの変動
  • 機会
    • 心臓POC検査の改善と継続的な進歩
    • 検査能力を向上させる新しいバイオマーカーの開発の進歩
  • 課題
    • 心臓POC検査における運用上および技術的な複雑さ
• 市場セグメンテーション分析
  • 製品：クリニック全体でマルチプレックス検査の需要が増加
  • バイオマーカーの種類：心臓の早期発見のための心臓型脂肪酸結合タンパク質（H-FABP）と虚血修飾アルブミン（IMA）の需要増加
  • エンドユーザー：サンプル容量が大きい複雑なシステムの診断ラボにおける心臓POC検査の利用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 心臓POC検査市場：製品別

• アナライザー
• キットとアッセイ
• ソフトウェアとサービス

第7章 心臓POC検査市場バイオマーカーの種類別

• 心臓トロポニン
• CK-MB分画
• Dダイマー
• 心臓型脂肪酸結合タンパク質（H-FABP）
• ホモシステイン
• hs C反応性タンパク質（CRP）
• 虚血修飾アルブミン（IMA）
• ミオグロビン
• ナトリウム利尿ペプチド（NP）
  • 心房性ナトリウム利尿ペプチド（ANP）
  • B型ナトリウム利尿ペプチド（BNP）
  • N末端プロBNP（NT-プロBNP）
• sCD40L

第8章 心臓POC検査市場：エンドユーザー別

• 診断検査室
• 病院・クリニック
• 調査・学術機関

第9章 南北アメリカの心臓POC検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の心臓POC検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの心臓POC検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Hiproのポイントオブケア診断がインドで発売
  • ジャナ・ケア、ロシュと提携し、慢性腎臓病および心臓病患者の遠隔ケア改善に向けた血液検査プラットフォームの開発と配布を開始
  • シプラが診断ポートフォリオを拡大し、ポイントオブケア検査装置を発売
• 戦略分析と提言

企業一覧

• Abaxis, Inc. by Zoetis Inc
• Abbott Laboratories
• ACON Laboratories, Inc.
• Beckman Coulter
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Cardiac Insight Inc.
• CardioGenics Holdings Inc.
• Chembio Diagnostic Systems, Inc. by Biosynex
• EKF Diagnostics
• F. Hoffmann-La Roche Ltd.
• Fujirebio
• Horiba, Ltd.
• I-Sens Inc.
• LifeSign LLC
• Nexus Dx, Inc. by Sinocare
• Nova Biomedical
• PTS Diagnostics by Danaher Corporation
• Quidel Corporation
• Radiometer Medical ApS
• Randox Laboratories Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Trividia Health, Inc.

LIST OF FIGURES

• FIGURE 1. CARDIAC POINT OF CARE TESTING MARKET RESEARCH PROCESS
• FIGURE 2. CARDIAC POINT OF CARE TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CARDIAC POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CARDIAC POINT OF CARE TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CARDIAC TROPONINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK-MB FRACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY D-DIMER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART-TYPE FATTY ACID-BINDING PROTEIN (H-FABP), BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOMOCYSTEINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HS C-REACTIVE PROTEIN (CRP), BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ISCHEMIA-MODIFIED ALBUMIN (IMA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ATRIAL NATRIURETIC PEPTIDE (ANP), BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE (BNP), BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY N-TERMINAL PROBNP (NT-PROBNP), BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SCD40L, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 46. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 67. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 68. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 70. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 71. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 72. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 75. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 79. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 80. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 83. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 84. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 87. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 88. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 92. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 96. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 99. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 100. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 103. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 104. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 107. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 108. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 116. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 117. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 120. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 121. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 124. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 125. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 128. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 129. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 132. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 133. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 136. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 137. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 140. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 141. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 145. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 148. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 149. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 152. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 153. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 156. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 157. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 159. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 160. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 161. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 164. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 165. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 177. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 180. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 181. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 184. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 185. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 188. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 189. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 196. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 199. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Cardiac Point of Care Testing Market was valued at USD 8.31 billion in 2023, expected to reach USD 9.38 billion in 2024, and is projected to grow at a CAGR of 13.14%, to USD 19.74 billion by 2030.

Cardiac Point of Care Testing (POCT) refers to medical diagnostic testing performed at or near the site of patient care, aimed at swiftly identifying cardiac conditions like heart attacks or heart failure. The necessity for cardiac POCT stems from the urgent need for rapid diagnosis and treatment of cardiovascular diseases, which remain a leading cause of mortality globally. Its primary applications include emergency departments, intensive care units, and other critical scenarios where quick results can significantly improve patient outcomes. The end-use scope extends to hospitals, clinics, ambulatory care settings, and even home care, reflecting its versatility and importance in healthcare delivery.

From a market perspective, the increasing prevalence of cardiovascular diseases, coupled with advancements in technology such as miniaturized biosensors, is driving the growth of cardiac POCT. Growing demand for rapid testing, especially in remote or resource-limited settings, further amplifies its significance. However, challenges like high costs of advanced POCT devices, regulatory hurdles, and variable accuracy compared to laboratory testing can impede market growth. A key opportunity lies in expanding access through cost-effective solutions and enhanced accuracy, potentially by integrating AI and machine learning for improved predictive analytics.

Despite these challenges, the cardiac POCT market offers significant innovation opportunities, particularly in the development of multi-analyte POCT devices capable of delivering comprehensive panel testing from a single sample. Encouraging collaborative efforts between technology developers and healthcare providers can foster the creation of more user-friendly and efficient tests. Businesses could benefit by focusing on geographic regions with limited healthcare infrastructure but high cardiac disease prevalence, creating tailored solutions to meet unmet needs.

In summary, while the cardiac POCT market faces limitations, such as cost and regulatory issues, it presents ripe opportunities by addressing technological improvements and expanding applications. Strategic innovation and collaboration efforts can harness these opportunities to drive sustained market growth and improved patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac Point of Care Testing Market

The Cardiac Point of Care Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidences of cardiovascular disorders among the population
  • Favorable government initiatives for the introduction of POC testing
  • Improving healthcare expenditure across economies worldwide
• Market Restraints
  • Fluctuating cost of materials and components used in cardiac POC testing
• Market Opportunities
  • Improvements and continuous advancements in cardiac POC testing
  • Advances in the development of new biomarkers to improve testing capabilities
• Market Challenges
  • Operational and technical complexities in cardiac POC testing

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac Point of Care Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac Point of Care Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac Point of Care Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac Point of Care Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac Point of Care Testing Market

A detailed market share analysis in the Cardiac Point of Care Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac Point of Care Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac Point of Care Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac Point of Care Testing Market

A strategic analysis of the Cardiac Point of Care Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Point of Care Testing Market, highlighting leading vendors and their innovative profiles. These include Abaxis, Inc. by Zoetis Inc, Abbott Laboratories, ACON Laboratories, Inc., Beckman Coulter, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardiac Insight Inc., CardioGenics Holdings Inc., Chembio Diagnostic Systems, Inc. by Biosynex, EKF Diagnostics, F. Hoffmann-La Roche Ltd., Fujirebio, Horiba, Ltd., I-Sens Inc., LifeSign LLC, Nexus Dx, Inc. by Sinocare, Nova Biomedical, PTS Diagnostics by Danaher Corporation, Quidel Corporation, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trividia Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Cardiac Point of Care Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Analyzers, Kits & Assays, and Software & Services.
• Based on Biomarker Type, market is studied across Cardiac Troponins, CK-MB Fraction, D-Dimer, Heart-Type Fatty Acid-Binding Protein (H-FABP), Homocysteine, hs C-reactive Protein (CRP), Ischemia-Modified Albumin (IMA), Myoglobin, Natriuretic Peptides (NPs), and sCD40L. The Natriuretic Peptides (NPs) is further studied across Atrial Natriuretic Peptide (ANP), B-type Natriuretic Peptide (BNP), and N-terminal proBNP (NT-proBNP).
• Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of cardiovascular disorders among the population
    • 5.1.1.2. Favorable government initiatives for the introduction of POC testing
    • 5.1.1.3. Improving healthcare expenditure across economies worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. Fluctuating cost of materials and components used in cardiac POC testing
  • 5.1.3. Opportunities
    • 5.1.3.1. Improvements and continuous advancements in cardiac POC testing
    • 5.1.3.2. Advances in the development of new biomarkers to improve testing capabilities
  • 5.1.4. Challenges
    • 5.1.4.1. Operational and technical complexities in cardiac POC testing
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing demand for multiplex assays across clinics
  • 5.2.2. Biomarker Type: Increasing demand for heart-type fatty acid-binding protein (H-FABP) and ischemia-modified albumin (IMA) for early cardiac detection
  • 5.2.3. End-user: Rising usage of cardiac POC testing in diagnostic laboratories for complex systems with high sample capacities
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cardiac Point of Care Testing Market, by Product

• 6.1. Introduction
• 6.2. Analyzers
• 6.3. Kits & Assays
• 6.4. Software & Services

7. Cardiac Point of Care Testing Market, by Biomarker Type

• 7.1. Introduction
• 7.2. Cardiac Troponins
• 7.3. CK-MB Fraction
• 7.4. D-Dimer
• 7.5. Heart-Type Fatty Acid-Binding Protein (H-FABP)
• 7.6. Homocysteine
• 7.7. hs C-reactive Protein (CRP)
• 7.8. Ischemia-Modified Albumin (IMA)
• 7.9. Myoglobin
• 7.10. Natriuretic Peptides (NPs)
  • 7.10.1. Atrial Natriuretic Peptide (ANP)
  • 7.10.2. B-type Natriuretic Peptide (BNP)
  • 7.10.3. N-terminal proBNP (NT-proBNP)
• 7.11. sCD40L

8. Cardiac Point of Care Testing Market, by End-User

• 8.1. Introduction
• 8.2. Diagnostic Laboratories
• 8.3. Hospitals & Clinics
• 8.4. Research & Academic Institutes

9. Americas Cardiac Point of Care Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cardiac Point of Care Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cardiac Point of Care Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Hipro Point-of-Care Diagnostics Launched in India
  • 12.3.2. Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
  • 12.3.3. Cipla expands diagnostics portfolio, launches point-of-care testing device
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abaxis, Inc. by Zoetis Inc
• 2. Abbott Laboratories
• 3. ACON Laboratories, Inc.
• 4. Beckman Coulter
• 5. Becton, Dickinson and Company
• 6. Bio-Rad Laboratories, Inc.
• 7. bioMerieux SA
• 8. Cardiac Insight Inc.
• 9. CardioGenics Holdings Inc.
• 10. Chembio Diagnostic Systems, Inc. by Biosynex
• 11. EKF Diagnostics
• 12. F. Hoffmann-La Roche Ltd.
• 13. Fujirebio
• 14. Horiba, Ltd.
• 15. I-Sens Inc.
• 16. LifeSign LLC
• 17. Nexus Dx, Inc. by Sinocare
• 18. Nova Biomedical
• 19. PTS Diagnostics by Danaher Corporation
• 20. Quidel Corporation
• 21. Radiometer Medical ApS
• 22. Randox Laboratories Ltd.
• 23. Siemens Healthineers AG
• 24. Thermo Fisher Scientific Inc.
• 25. Trividia Health, Inc.